Tolerance and complications in a multicenter trial of intravenous APSAC and intracoronary streptokinase in acute myocardial infarction.
Adverse events data of a randomized, multicenter, angiographically controlled trial of intracoronary streptokinase and intravenous anistreplase, or anisoylated plasminogen streptokinase activator complex (APSAC) are presented. The frequency of severe adverse events is similar for streptokinase and anistreplase; no unexpected adverse experiences were reported with either drug. The most frequently encountered side effect was bleeding, overwhelmingly from the groin puncture site from angiography.
Rothbard
R L
RL
University of Rochester School of Medicine, New York.
Anderson
J L
JL
Fitzpatrick
P G
PG
Hakworthy
R A
RA
Sorensen
S G
SG
Marder
V J
VJ
D000208:Acute Disease; D000792:Angiography; D016255:Anistreplase; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D015337:Multicenter Studies as Topic; D009203:Myocardial Infarction / Q000188:drug therapy*; D010958:Plasminogen / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D011677:Punctures / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D013300:Streptokinase / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D016255:Anistreplase; D010958:Plasminogen; D013300:Streptokinase